Searched for
CDMO BUSINESS
Gland Pharma shares jump 4% after Q2 profit jumps 58%, revenue rises 23% YoYGland Pharma shares rose 3.89% after reporting strong Q2 FY27 results, with revenue growing 23% and net profit jumping 58% year-on-year. Th...- Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its t...
- Divi's Labs shares jump 8% to fresh 52-week high after Q2 profit soars 64% YoY. What brokerages say after bumper results?Divi’s Laboratories shares surged over 8% during Muhurat Trading, hitting a 52-week high after Q2 FY27 net profit jumped 64% to ₹1,127 cror...
- PSBs, pharma and defence: HDFC Securities CEO names Samvat 2083’s dark horsesHDFC Securities MD and CEO Dhiraj Relli identifies public sector banks, pharmaceuticals and defence as potential outperformers in Samvat 20...
- More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger rolesIndia's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers bus...
- Pharma industry steps up API investments to cut import dependence, move up value chainIndia's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Invest...
- Alivus Life Sciences block deal: Promoter Nirma sells over 28 lakh shares worth Rs 390 crore; Norges Bank, Helios MF among buyersNirma sold 28.46 lakh Alivus Life Sciences shares worth Rs 390 crore through a block deal at Rs 1,370 apiece. Norges Bank, Bandhan MF and o...
- Pills are paying off! Pharma stocks lead 2026 rally with up to 112% returnIn 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic dem...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analystsGlobal markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at ...
- Beyond tech: Kotak MF’s Shibani Kurian on India’s next innovation-led winnersInnovation-led investment opportunities in India are extending well beyond technology, with healthcare, auto components and industrials eme...
- Diwali investment picks 2026: 10 fund managers reveal promising opportunities and risks to watchThis Diwali, investment experts advise a strategic approach focused on asset allocation rather than luring high-growth stocks. Sectors like...
- How Indian investors’ portfolios are changing: From property and gold to SIPs and ETFsIndian households are re-evaluating their asset allocations as gold holdings rise and equity investments remain stable. Recent data reveals...
- Diwali 2026: 77 stocks knock down D-St bears to deliver multibagger returns of up to 4,700% in a yearWith Diwali 2026 on the horizon, 77 stocks have thrived despite market fluctuations, marking exceptional returns. Mrugesh Trading showcases...
- Laurus Labs shares climb 4% after Q2 profit zooms 126% YoYLaurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results. Revenue increased 33% year-on-ye...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhen a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling u...
- Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini PiramalIn a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The ...
- Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...
- From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plansBiodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture ...
- From CDMO to aerospace: How Vikas Khemani finds India’s next big themesNow, as Carnelian has ventured into mutual fund business by launching a small-cap fund with a ₹5,000 crore cap, Khemani is focusing on manu...
- Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upsideNuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating and a target price of Rs 2,520, implying a 24% upsi...
Load More
